CN115667281A - 用于预防或治疗共核蛋白病的肽 - Google Patents

用于预防或治疗共核蛋白病的肽 Download PDF

Info

Publication number
CN115667281A
CN115667281A CN202180036867.0A CN202180036867A CN115667281A CN 115667281 A CN115667281 A CN 115667281A CN 202180036867 A CN202180036867 A CN 202180036867A CN 115667281 A CN115667281 A CN 115667281A
Authority
CN
China
Prior art keywords
synuclein
peptide
fabp3
amino acid
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036867.0A
Other languages
English (en)
Chinese (zh)
Inventor
福永浩司
川畑伊知郎
河田康志
沟端知宏
福井直也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of CN115667281A publication Critical patent/CN115667281A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180036867.0A 2020-07-29 2021-07-07 用于预防或治疗共核蛋白病的肽 Pending CN115667281A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-127958 2020-07-29
JP2020127958 2020-07-29
PCT/JP2021/025577 WO2022024693A1 (ja) 2020-07-29 2021-07-07 シヌクレイノパチーを予防又は治療するために使用されるペプチド

Publications (1)

Publication Number Publication Date
CN115667281A true CN115667281A (zh) 2023-01-31

Family

ID=80036234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036867.0A Pending CN115667281A (zh) 2020-07-29 2021-07-07 用于预防或治疗共核蛋白病的肽

Country Status (5)

Country Link
US (1) US20230242601A1 (https=)
EP (1) EP4190797A4 (https=)
JP (1) JP7849854B2 (https=)
CN (1) CN115667281A (https=)
WO (1) WO2022024693A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192147A1 (ja) * 2024-03-15 2025-09-18 公益財団法人東京都医学総合研究所 αシヌクレインの蓄積抑制用の組成物、及びその利用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
JP2005517389A (ja) * 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
US20180134775A1 (en) * 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
CN110506057A (zh) * 2017-02-17 2019-11-26 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2005108423A1 (en) * 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
PL2118300T3 (pl) * 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US20200095296A1 (en) * 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517389A (ja) * 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
US20180134775A1 (en) * 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
CN110506057A (zh) * 2017-02-17 2019-11-26 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT W. NEWBERRY等: "Deep mutational scanning reveals the structural basis for α-synuclein activity", NATURE CHEMICAL BIOLOGY, vol. 16, no. 6, 9 March 2020 (2020-03-09), pages 656, XP037145342, DOI: 10.1038/s41589-020-0480-6 *

Also Published As

Publication number Publication date
EP4190797A4 (en) 2024-09-04
JP7849854B2 (ja) 2026-04-22
WO2022024693A1 (ja) 2022-02-03
JP2022027513A (ja) 2022-02-10
US20230242601A1 (en) 2023-08-03
EP4190797A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
Rose-John IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6
Campana et al. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury
US8748384B2 (en) Modulation of activity of proneurotrophins
EP3816625B1 (en) Compositions and methods for growth factor modulation
US6780971B2 (en) Compositions for inhibiting the aggregation pathway of α-synuclein
CA2461305C (en) Methods of suppressing microglial activation and systemic inflammatory responses
EP2282728B1 (en) Modulation of the Vps10p-domain receptors.
US20220380454A1 (en) Methods and compositions for treating alzheimer's disease
CN113966224A (zh) 采用补体抑制剂的炎性疾病治疗
Houghton et al. Architecture and regulation of a GDNF-GFRα1 synaptic adhesion assembly
Asari et al. Structural basis for the effective myostatin inhibition of the mouse myostatin prodomain-derived minimum peptide
JP2024113090A (ja) 神経可塑性を誘導するための方法および組成物
ES2407454T3 (es) Métodos de tratamiento de trastornos neuronales utilizando péptidos MNTF y análogos de los mismos
CN115667281A (zh) 用于预防或治疗共核蛋白病的肽
CN105709224A (zh) 用于治疗与herv-w包膜蛋白表达相关的疾病中的髓鞘再生阻断的化合物
CA2802207A1 (en) Materials and method for suppressing inflammatory and neuropathic pain
CN103214555B (zh) 介导应激反应的肽抑制剂
KR101604377B1 (ko) Trpc3의 n-말단 부위에 결합하는 항체를 이용한 칼슘이온 관련 근육 질환의 예방 또는 치료용 조성물
JP4135810B2 (ja) アルツハイマー病関連蛋白質の調節とその利用
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
CN115531543A (zh) α-突触核蛋白C末端作为抗帕金森病药物的重要靶点
US20230374068A1 (en) Compositions and methods for treating a disease
Klymenko et al. From Hydra to Humans: Head Activator in Neurogenesis and Neurorepair
KR101634855B1 (ko) Trpc3와 trpc1 간의 이형복합체 형성을 저해하는 물질을 이용한 칼슘이온 관련 근육 질환의 예방 또는 치료용 조성물
Klymenko et al. From Hydra to Humans: Head Activator Peptide in Neurogenesis and Neurorepair

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination